Genetic Testing for Hereditary Hearing Loss

Policy # 00379
Original Effective Date: 12/18/2013
Current Effective Date: 08/09/2021

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Cochlear Implant is addressed separately in medical policy 00017.

Note: Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders is addressed separately in medical policy 00389.

When Services Are Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider genetic testing for hereditary hearing loss genes (GJB2, GJB6 and other hereditary hearing loss-related genes) in individuals with suspected hereditary hearing loss to confirm the diagnosis of hereditary hearing loss (see Policy Guidelines section) to be eligible for coverage.**

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider preconception genetic testing (carrier testing) for hereditary hearing loss genes (GJB2, GJB6 and other hereditary hearing loss-related genes) in parents to be eligible for coverage**:.*
Genetic Testing for Hereditary Hearing Loss

Policy # 00379
Original Effective Date: 12/18/2013
Current Effective Date: 08/09/2021

Patient Selection Criteria
Coverage eligibility will be considered when at least ONE of the following criteria is met:
- Offspring with hereditary hearing loss; OR
- One or both parents with suspected hereditary hearing loss; OR
- First- or second-degree relative affected with hereditary hearing loss; OR
- First-degree relative with offspring who is affected with hereditary hearing loss.

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers genetic testing for hereditary hearing loss genes for all other situations, including but not limited to, testing in patients without hearing loss to be investigational.*

The use of genetic testing for hereditary hearing loss genes when patient selection criteria are not met is considered to be investigational.*

Policy Guidelines
Hereditary hearing loss can be classified as syndromic or nonsyndromic. The definition of nonsyndromic hearing loss is hearing loss not associated with other physical signs and symptoms at the time of hearing loss presentation. It is differentiated from syndromic hearing loss, which is hearing loss associated with other signs and symptoms characteristic of a specific syndrome. Physical signs of a syndrome often include dysmorphic changes in the maxillofacial region and/or malformations of the external ears. Malfunction of internal organs may also be part of a syndrome. The physical signs can be subtle and easily missed on physical exam; therefore, exclusion of syndromic findings is ideally done by an individual with expertise in identifying dysmorphic physical signs. The phenotypic presentation of nonsyndromic hearing loss varies, but generally involves the following features:
- Sensorineural hearing loss
- Mild-to-profound (more commonly) degree of hearing impairment
- Congenital onset
- Usually nonprogressive

*©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Genetic Testing for Hereditary Hearing Loss

Policy # 00379
Original Effective Date: 12/18/2013
Current Effective Date: 08/09/2021

This policy primarily focuses on the use of genetic testing to identify a cause of suspected hereditary hearing loss. The diagnosis of syndromic hearing loss can be made on the basis of associated clinical findings. However, at the time of hearing loss presentation, associated clinical findings may not be apparent; furthermore, variants in certain genetic loci may cause both syndromic and nonsyndromic hearing loss. Given this overlap, the policy focuses on genetic testing for hereditary hearing loss more generally.

In addition to pathogenic variants in the GJB6 and GJB2 genes, there are many less common pathogenic variants found in other genes. They include: ACTG1, CDH23, CLDN14, COCH, COL11A2, DFNA5, DFNB31, DFNB59, ESPN, EYA4, GJB2, GJB6, KCNQ4, LHFPL5, MT-TS1, MYO15A, MYO6, MYO7A, OTOF, PCDH15, POU3F4, SLC26A4, STRC, TECTA, TMC1, TMIE, TMPRSS3, TRIOBP, USH1C, and WFS1 genes.

Targeted testing for variants associated with hereditary hearing loss should be confined to known pathogenic variants. While research studies using genome-wide associations have uncovered numerous single nucleotide variants and copy number variations associated with hereditary hearing loss, the clinical significance of these findings is unclear.

For carrier testing, outcomes are expected to improve if parents alter their reproductive decision making as a result of genetic test results. This may occur through the use of preimplantation genetic testing in combination with in vitro fertilization. Other ways that prospective parents may alter their reproductive choices are to proceed with attempts at pregnancy or to avoid attempts at pregnancy, based on carrier testing results.

Testing Strategy
Evaluation of a patient with suspected hereditary hearing loss should involve a careful physical exam and family history to assess for associated clinical findings that may point to a specific syndromic or nonsyndromic cause of hearing loss (eg, infectious, toxic, autoimmune, other causes). Consideration should also be given to temporal bone computed tomography scanning in cases of progressive hearing loss and to testing for cytomegalovirus in infants with sensorineural hearing loss.

If there is no high suspicion for a specific hearing loss etiology, ideally the evaluation should occur in a stepwise fashion. About 50% of individuals with autosomal recessive hereditary hearing loss
have pathogenic variants in the *GJB2* gene. In the remainder of patients with apparent autosomal recessive hereditary hearing loss, numerous other genes are implicated. In autosomal dominant hereditary hearing loss, there is no single identifiable gene responsible for most cases. If there is suspicion for autosomal recessive congenital hearing loss, it would be reasonable, to begin with testing of *GJB2* and *GJB6*. If this is negative, screening for the other genes associated with hearing loss with a multigene panel would be efficient. An alternative strategy for suspected autosomal recessive or autosomal dominant hearing loss would be to obtain a multigene panel that includes *GJB2* and *GJB6* as a first step. Given the extreme heterogeneity in genetic causes of hearing loss, these 2 strategies may be considered reasonably equivalent.

**Genetics Nomenclature Update**

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It was implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). The Society’s nomenclature is recommended by the Human Variome Project, the Human Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology—“pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”—to describe variants identified that cause Mendelian disorders.

**Table PG1. Nomenclature to Report on Variants Found in DNA**

<table>
<thead>
<tr>
<th>Previous</th>
<th>Updated</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutation</td>
<td>Disease-associated variant</td>
<td>Disease-associated change in the DNA sequence</td>
</tr>
<tr>
<td>Variant</td>
<td>Change in the DNA sequence</td>
<td></td>
</tr>
</tbody>
</table>
Genetic Testing for Hereditary Hearing Loss

Policy # 00379
Original Effective Date: 12/18/2013
Current Effective Date: 08/09/2021

| Familial variant | Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives |

Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

<table>
<thead>
<tr>
<th>Variant Classification</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathogenic</td>
<td>Disease-causing change in the DNA sequence</td>
</tr>
<tr>
<td>Likely pathogenic</td>
<td>Likely disease-causing change in the DNA sequence</td>
</tr>
<tr>
<td>Variant of uncertain significance</td>
<td>Change in DNA sequence with uncertain effects on disease</td>
</tr>
<tr>
<td>Likely benign</td>
<td>Likely benign change in the DNA sequence</td>
</tr>
<tr>
<td>Benign</td>
<td>Benign change in the DNA sequence</td>
</tr>
</tbody>
</table>

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

Genetic Counseling
Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

Background/Overview
Hereditary Hearing Loss
Hearing loss is a common birth defect. Approximately 1 in 500 newborns in developed countries is affected by bilateral, permanent hearing loss of moderate or greater severity (≥40 decibels).
Syndromic hearing loss refers to hearing loss associated with other medical or physical findings, including visible abnormalities of the external ear. Because syndromic hearing loss occurs as part of a syndrome of multiple clinical manifestations, it is often recognized more readily as hereditary.

Nonsyndromic hearing loss is defined as hearing loss not associated with other physical signs or symptoms. For nonsyndromic hearing loss, it is more difficult to determine whether the etiology is hereditary or acquired because, by definition, there are no other clinical manifestations at the time of the hearing loss presentation. Nonsyndromic hearing loss accounts for 70% to 80% of genetically determined deafness.

Autosomal recessive patterns of inheritance predominate and account for 80% of congenital nonsyndromic hearing loss. A typical clinical presentation of autosomal recessive nonsyndromic hearing loss involves the following characteristics:

- Sensorineural hearing loss
- Mild-to-profound (more commonly) degree of hearing impairment
- Congenital onset
- Usually nonprogressive
- No associated medical findings.

Most of the remaining 20% of patients have an autosomal dominant inheritance pattern with a small number having X-linked or mitochondrial inheritance. Patients with autosomal dominant inheritance typically show progressive nonsyndromic hearing loss, which begins in the second through fourth decades of life.

**Diagnosis**

Diagnosis of nonsyndromic hearing loss requires an evaluation by appropriate core medical personnel with expertise in the genetics of hearing loss, dysmorphology, audiology, otolaryngology, genetic counseling, and communication with deaf patients. The evaluation should include family history, as well as a physical examination consisting of otologic examination, airway examination, documentation of dysmorphisms, and neurologic evaluation. However, the clinical diagnosis of nonsyndromic hearing loss is nonspecific because there are a number of underlying etiologies, and often it cannot be determined with certainty whether a genetic cause for hearing loss exists.
Genetic Testing for Hereditary Hearing Loss

Policy #  00379
Original Effective Date:  12/18/2013
Current Effective Date:  08/09/2021

Treatment
Treatment of congenital and early-onset hearing loss typically involves enrollment in an educational curriculum for hearing impaired persons and fitting with an appropriate hearing aid. In some patients with profound deafness, a cochlear implant can be performed. Early identification of infants with hearing impairment may be useful in facilitating early use of amplification by 6 months of age, and early intervention to achieve age-appropriate communication, speech, and language development. Delays in the development of hearing treatment have been shown to delay development of communication. The primary method for identification of hearing impairment has been newborn screening with audiometry. Genetic testing has not been proposed as a primary screen for hearing loss.

Genetics of Hereditary Hearing Loss
Genes associated with hereditary hearing loss may be associated with an autosomal dominant, autosomal recessive, X-linked, or mitochondrial inheritance pattern. The genetic loci on which variants associated with hereditary hearing loss are usually found are termed DFN, and hereditary hearing loss is sometimes called DFN-associated hearing loss. DFN loci are named based on their mode of inheritance: DFNA associated with autosomal dominant inheritance; DFNB with autosomal recessive inheritance; and DFNX with X-linked inheritance.

Two DFN loci commonly associated with hereditary hearing loss are DFNA3 and DFNB1, both of which map to chromosome 13q12. DFNA3-associated hereditary hearing loss is caused by autosomal dominant pathogenic variants present in the GJB2 or GJB6 genes. DFNB1-associated hereditary hearing loss relates to autosomal recessive syndromes in which more than 99% of cases are caused by pathogenic variants in the GJB2 gene, and less than 1% of remaining cases arise from pathogenic variants to GJB6. A list of available tests for genes at the DFNA3 and DFNB1 loci are provided in Table 1.

Two of the most commonly disease-associated genes are GJB2 and GJB6. GJB2 is a small gene with a single coding exon. Variants of this gene are most common in hereditary hearing loss, causing an estimated 50% of the cases of hereditary nonsyndromic hearing loss. The carrier rate in the general population for a recessive deafness-causing GJB2 variant is approximately 1 in 33. Specific variants have been observed to be more common in certain ethnic populations. Variants in the GJB2 gene will impact the expression of the Cx26 connexin protein, and almost always cause prelingual but not necessarily congenital, deafness. Different variants of GJB2 can present high phenotypic variation
but it has been demonstrated that it is possible to correlate the type of associated hearing loss with findings on molecular analysis. A systematic review by Chan and Chang (2014), reporting on GJB2 variant prevalence, suggested the overall prevalence of GJB2 variants is similar around the world, although specific variants differ.

Variants in the GJB6 gene lead to similar effects on abnormal expression of connexin protein Cx30. However, GJB6 variants are much less common than GJB2 variants. Of all patients with hereditary hearing loss, approximately 3% have a variant in the GJB6 gene.

**Table 1. Clinical Characteristics and Testing Methods for GJB2 and GJB6 Variants at the DFNA3 and DFNB1 Loci**

<table>
<thead>
<tr>
<th>Locus</th>
<th>Gene</th>
<th>Onset</th>
<th>Audio profile</th>
<th>Test Method</th>
<th>Variants Detected</th>
</tr>
</thead>
</table>
| DFNA3 | GJB2 | Prelingual | High-frequency progressive | • Sequence analysis/variant scanning  
• Targeted variant analysis  
• Deletion/duplication analysis | • Sequence variants  
• Specified sequence variants  
• Exonic or whole-gene deletions/duplications |
| DFNA3 | GJB6 | Prelingual | High-frequency progressive | • Sequence analysis/variant scanning  
• Targeted variant analysis  
• Deletion/duplication analysis | • Sequence variants  
• Specified sequence variants  
• Exonic or whole-gene deletions/duplications |
| DFNB1 | GJB2 | Prelingual | Usually stable | • Targeted variant analysis  
• Deletion/duplication analysis | • GJB2 sequence variants  
• Exon(s) or whole-gene deletions |
Genetic Testing for Hereditary Hearing Loss

Policy # 00379
Original Effective Date: 12/18/2013
Current Effective Date: 08/09/2021

### DFNB1 | GJB6 | Prelingual | Usually stable | • Deletion/duplication analysis | • GJB6 deletions
---|---|---|---|---|---

Analysis for GJB6 and GJB2 variants can be performed by Sanger sequencing of individual genes. This method has a high degree of validity and reliability but is limited by the ability to sequence 1 gene at a time. With Sanger sequencing, the genes with the most common pathogenic variants are generally sequenced first, followed by sequencing of additional genes if a pathogenic variant is not found.

In addition to the most common genes associated with hereditary hearing loss (GJB6, GJB2), there are many less common disease-associated genes. Some are: ACTG1, CDH23, CLDN14, COCH, COL11A2, DFNA5, DFNB31, DFNB59, ESPN, EYA4, GJB2, GJB6, KCNQ4, LHFPL5, MT-TS1, MYO15A, MYO6, MY07A, OTOF, PCDH15, POU3F4, SLC26A4, STRC, TECTA, TMC1, TMIE, TMPRSS3, TRIOBP, USH1C, and WFS1 genes. Novel genetic variants continue to be identified in cases of hereditary hearing loss. For example, as of 2014, over 2000 pathogenic deafness variants in approximately 130 genes had been reported. In contrast, only 18 pathogenic copy number variants had been identified by 2014. Copy number variants, caused by insertions, deletions, or recombination, can lead to hearing loss from gene disruption or changes in the number of dose-sensitive genes. The gene most commonly associated with pathogenic copy number variants in hearing loss is STRC, which encodes stereocilin and is the most frequent cause of autosomal recessive causes of nonsyndromic hearing loss after pathogenic variants in GJB2.

Because a large number of genes are associated with hereditary hearing loss, there are various genetic panels for hereditary deafness. Next-generation sequencing technology allows targeted sequencing of multiple genes simultaneously, expanding the ability to examine multiple genes. These panels are alternatives to the sequencing of individual genes such as GJB6 and GJB2. These panels include the most common genes associated with nonsyndromic hearing loss. They may also include many of the less common genes associated with nonsyndromic hearing loss, as well as genes associated with syndromic hearing loss. Also, whole-exome sequencing and whole-genome sequencing have been used to identify novel variants in subjects with a history suggestive of genetic hereditary hearing loss. Targeted genomic enrichment coupled with massively parallel sequencing can be used to identify both single nucleotide variants and copy number variants.
Overlap Between Nonsyndromic Hearing Loss and Recognized Syndromes

There is overlap between hereditary nonsyndromic hearing loss and syndromic hearing loss associated with recognized syndromes. Some genetic variants may be associated with clinical findings other than hearing loss but they are not necessarily manifest at the time of presentation with hearing loss. For example, Jervell and Lange-Nielsen syndrome is associated with congenital deafness and prolonged QT interval, but it may present only with deafness without an apparent history to suggest cardiac dysfunction. Additionally, some genes associated with nonsyndromic hearing loss are associated with recognized syndromes. Some genetic syndromes and genes that may overlap with nonsyndromic hearing loss are shown in Table 2.

Table 2. Genes With Overlap Between Syndromic and Nonsyndromic Hearing Loss

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Inheritance</th>
<th>Clinical Description</th>
<th>Gene</th>
<th>Reason for Overlap With NSHL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Usher syndrome</td>
<td>For all types: autosomal recessive</td>
<td>For all types: sensorineural HL with retinitis pigmentosa</td>
<td>MYO7A, USH1C, CDH23, PCDH15, SANS, CIB2</td>
<td>• Retinitis pigmentosa usually not apparent in first decade</td>
</tr>
<tr>
<td>Type 1</td>
<td></td>
<td>• Congenital severe-to-profound HL</td>
<td></td>
<td>• DFN18 (nonsyndromic) may also be caused by variants in USH1C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Abnormal vestibular function</td>
<td></td>
<td>• DFN12 (non-syndromic) may also be caused by variants in CDH23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• DFN2 (non-syndromic) and</td>
</tr>
</tbody>
</table>
### Genetic Testing for Hereditary Hearing Loss

**Policy #** 00379  
**Original Effective Date:** 12/18/2013  
**Current Effective Date:** 08/09/2021

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Inheritance</th>
<th>Clinical Description</th>
<th>Gene</th>
<th>Reason for Overlap With NSHL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2</td>
<td></td>
<td>• Congenital mild-to-severe HL</td>
<td>USH2A, VLGR1, WHRN</td>
<td>DFNA11 (non-syndromic) may also be caused by variants in MYO7A</td>
</tr>
<tr>
<td>Type 3</td>
<td></td>
<td>• Progressive HL</td>
<td>CLRN1i PDZD7</td>
<td></td>
</tr>
</tbody>
</table>
| Pendred syndrome                | Autosomal recessive| • Congenital sensorineural HL                                                           | SLC26A4 (50%)         | • Goiter not present until early puberty or adulthood  
|                                 |                   | • Bony labyrinth abnormalities (Mondini dysplasia or dilated vestibular aqueduct)      |                       | • Variants in SLC26A4 may also cause NSHL                                                    |
| Jervell and Lange-Nielsen       | Autosomal recessive| • Congenital deafness                                                                   | KCNQ1, KCNE1          | • HL may present without personal or family history of cardiac symptoms (sudden death, SIDS, |

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
### Wolfram syndrome

- **Inheritance**: Autosomal recessive
- **Clinical Description**:
  - Progressive sensorineural HL
  - Diabetes
  - Optic atrophy
  - Progressive neurologic abnormalities
- **Gene**: WFS1
- **Reason for Overlap With NSHL**: WFS1-associated HL (DFNA6, DFNA4, DFNA38; congenital HL without associated findings) may also be caused by variants in WFS1

HL: hearing loss; NSHL: nonsyndromic hearing loss; SIDS: sudden infant death syndrome.

### FDA or Other Governmental Regulatory Approval

**U.S. Food and Drug Administration (FDA)**

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Molecular diagnostic testing is available under the auspices of the CLIA. Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

### Rationale/Source

**Description**

Hearing loss is a common birth defect. Approximately 1 in 500 newborns in developed countries is affected by bilateral, permanent hearing loss of moderate or greater severity (≥40 decibels). Syndromic hearing loss refers to hearing loss associated with other medical or physical findings, including visible abnormalities of the external ear. Because syndromic hearing loss occurs as part of a syndrome of multiple clinical manifestations, it is often recognized more readily as hereditary. Nonsyndromic hearing loss is defined as hearing loss not associated with other physical signs or
symptoms. Nonsyndromic hearing loss accounts for 70% to 80% of genetically determined deafness, and it is more difficult to determine whether the etiology is hereditary or acquired.

**Summary of Evidence**

For individuals who are suspected of having hereditary nonsyndromic hearing loss who receive genetic testing, the evidence includes small retrospective, single-center studies, case reports, case series, and genotype-phenotype correlation studies evaluating the clinical validity and testing yield for nonsyndromic hearing loss. Relevant outcomes are test accuracy and validity, changes in reproductive decision making, morbid events, and resource utilization. Genetic variants in *GJB2*, *GJB6*, and numerous other genes are found in a substantial percentage of patients with hereditary hearing loss. Of all patients with suspected hereditary hearing loss after clinical examination, a substantial proportion will be found to have a genetic variant. The probability of finding a genetic variant is increasing as new variants are identified. False-positive results on genetic testing are expected to be very low. For diagnosis, there are a number of potential benefits of genetic testing, including a reduction in the need for alternative diagnostic tests and monitoring of patients with genetically identified syndromic hearing loss associated with other medical conditions. Clinical guidelines have recommended a tiered genetic testing approach, starting with the most common genes. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with a family history of hereditary nonsyndromic hearing loss who receive preconception genetic testing to determine carrier status, the evidence is limited but includes clinical guidelines. Relevant outcomes are test accuracy and validity, changes in reproductive decision making, morbid events, and resource utilization. Genetic variants in *GJB2*, *GJB6*, and numerous other genes are found in a substantial percentage of patients with hereditary hearing loss. The probability of finding a genetic variant is increasing as new gene variants are identified. False-positive results on genetic testing are expected to be very low. There are several situations for which there is potential clinical utility of testing for genes associated with hereditary hearing loss. For parents at high-risk of having offspring with hereditary hearing loss, genetic testing can be useful as an aid in reproductive decision making. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.
Additional Information

2013 Input
In response to requests, clinical input was received from 2 physician specialty societies and 2 academic medical centers in 2013.

For individuals who have suspected hereditary nonsyndromic hearing loss who receive genetic testing, clinical input demonstrated support for genetic testing to differentiate hereditary hearing loss from other causes of hearing loss, and to improve the efficiency of the diagnostic workup by avoiding unnecessary testing. Clinical input has also suggested that knowledge of specific pathogenic variants may lead to further management changes, such as referral to specialists. Therefore, genetic testing to confirm the diagnosis of hereditary hearing loss may be considered medically necessary.

For individuals who have a family history of hereditary nonsyndromic hearing loss who receive preconception genetic testing to determine carrier status, genetic testing for hereditary hearing loss carrier status may be considered medically necessary when 1 of the following is present: (1) an offspring with suspected hereditary hearing loss, (2) 1 or both parents with suspected hereditary hearing loss, (3) a first-degree relative with an offspring who has hereditary hearing loss, or (4) a first- or second-degree relative with hereditary hearing loss and the parents desire to have further offspring and want to know the likelihood of another offspring with hereditary hearing loss.

Supplemental Information
Clinical Input From Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from 2 physician specialty societies and 2 academic medical centers while this policy was under review in 2013. Reviewers agreed with the medically necessary indication for carrier testing, and with additional indications for carrier testing. There was support for testing the index case to confirm nonsyndromic hearing loss among most reviewers. Reviewers in favor of genetic testing cited the ability to distinguish nonsyndromic hearing loss from
Genetic Testing for Hereditary Hearing Loss

Policy # 00379
Original Effective Date: 12/18/2013
Current Effective Date: 08/09/2021

other causes of hearing loss, to streamline the diagnostic workup and avoid further unnecessary testing, and to provide referrals to specialists when specific types of pathogenic variants identified are associated with disorders in other organ systems. It was considered that 2 contextual factors were present: barriers to performing high-quality trials and the potential to reduce harms by avoiding unnecessary testing.

Practice Guidelines and Position Statements

American College of Medical Genetics and Genomics
In 2014, the American College of Medical Genetics and Genomics issued practice guidelines for the clinical evaluation and etiologic diagnosis of hearing loss. The guidelines recommended obtaining testing for acquired hearing loss if there is clinical suspicion, including testing for cytomegalovirus, imaging, or other testing based on the suspected etiology. For individuals lacking physical findings suggestive of a known syndrome and having medical and birth histories not suggestive of an environmental cause of hearing loss, the guidelines made the following recommendations for a tiered diagnostic approach:

- Pretest genetic counseling should be provided, and, with patient’s informed consent, genetic testing should be ordered.
  - Single-gene testing may be warranted in cases in which the medical or family history, or presentation of the hearing loss, suggests a specific etiology. For example, testing for mitochondrial DNA mutations associated with aminoglycoside ototoxicity may be considered for individuals with a history of use of aminoglycoside antibiotics.
  - In the absence of any specific clinical indications and for singleton cases and cases with apparent autosomal recessive inheritance, the next step should be testing for DFNB1-related hearing loss (due to mutations in GJB2 and adjacent deletions in GJB6).
  - If initial genetic testing is negative, genetic testing using gene panel tests, NGS [next-generation sequencing] technologies such as large sequencing panels targeted toward hearing loss-related genes, whole-exome sequencing, or whole-genome sequencing may be considered. Because several tests are clinically available, the clinician must be aware of the genes included in the test (panel) chosen and the performance characteristics of the platform chosen, including coverage, analytic sensitivity, and what types of mutations will be detected....
Genetic Testing for Hereditary Hearing Loss

Policy # 00379
Original Effective Date: 12/18/2013
Current Effective Date: 08/09/2021

- If genetic testing reveals mutation(s) in a hearing loss-related gene, mutation-specific genetic counseling should be provided, followed by appropriate medical evaluations and referrals.”

American Academy of Pediatrics
In 2007, the American Academy of Pediatrics (AAP) issued recommendations on early hearing detection:

"Every infant with confirmed hearing loss and/or middle ear dysfunction should be referred for otologic and other medical evaluation. The purpose of these evaluations is to determine the etiology of hearing loss, to identify related physical conditions, and to provide recommendations for medical/surgical treatment as well as referral for other services. Essential components of the medical evaluation include clinical history, family history of childhood-onset permanent hearing loss, identification of syndromes associated with early- or late-onset permanent hearing loss, a physical examination, and indicated radiologic and laboratory studies (including genetic testing)."

"The evaluation, therefore, should include a review of family history of specific genetic disorders or syndromes, including genetic testing for gene mutations such as GJB2 (connexin-26), and syndromes commonly associated with early-onset childhood sensorineural hearing loss."

"All families of children with confirmed hearing loss should be offered, and may benefit from, a genetics evaluation and counseling. This evaluation can provide families with information on etiology of hearing loss, prognosis for progression, associated disorders (e.g., renal, vision, cardiac), and likelihood of recurrence in future offspring. This information may influence parents' decision-making regarding intervention options for their child."

The 2013 supplement to the AAP 2007 position statement on early intervention after confirmation of hearing loss in a child states in its recommendations for monitoring that parents or guardians should be educated about the "importance of medical, genetic, ophthalmologic, and cardiac (EKG) evaluations on children with any type and degree of hearing loss."
Genetic Testing for Hereditary Hearing Loss

Policy # 00379
Original Effective Date: 12/18/2013
Current Effective Date: 08/09/2021

Also in 2013 (reaffirmed June 2018), the AAP issued a policy statement on ethical issues in genetic testing of children. Following are some of their recommendations:

**General recommendations:**
"Decisions about whether to offer genetic testing and screening should be driven by the best interest of the child."

**Diagnostic testing:**
"In a child with symptoms of a genetic condition, the rationale for genetic testing is similar to that of other medical diagnostic evaluations. Parents or guardians should be informed about the risks and benefits of testing, and their permission should be obtained. Ideally and when appropriate, the assent of the child should be obtained."

**Newborn screening:**
"The AAP and ACMG [American College of Medical Genetics] support the mandatory offering of newborn screening for all children. After educating and counseling about the substantial benefits of newborn screening, its remote risks, and the next steps in the event of a positive screening result, parents should have the option of refusing the procedure, and an informed refusal should be respected."

**Carrier testing:**
"The AAP and ACMG do not support routine carrier testing in minors when such testing does not provide health benefits in childhood."

**Predictive gene testing:**
"Parents or guardians may authorize predictive genetic testing for asymptomatic children at risk of childhood-onset conditions. Ideally, the assent of the child should be obtained."

"Predictive genetic testing for adult-onset conditions should generally be deferred unless an intervention initiated in childhood may reduce morbidity or mortality."

**U.S. Preventive Services Task Force Recommendations**
Not applicable.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Genetic Testing for Hereditary Hearing Loss

Policy #  00379  
Original Effective Date:  12/18/2013  
Current Effective Date:  08/09/2021

Medicare National Coverage  
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials  
Some currently unpublished trials that might influence this review are listed in Table 3.

Table 3. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02082431</td>
<td>Long QT &amp; Hearing Loss Prospective Study Registry</td>
<td>600</td>
<td>Dec 2019</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

References


©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Genetic Testing for Hereditary Hearing Loss

Policy # 00379
Original Effective Date: 12/18/2013
Current Effective Date: 08/09/2021


Genetic Testing for Hereditary Hearing Loss

Policy # 00379
Original Effective Date: 12/18/2013
Current Effective Date: 08/09/2021


Policy History
Original Effective Date: 12/18/2013
Current Effective Date: 08/09/2021
12/12/2013 Medical Policy Committee review
12/18/2013 Medical Policy Implementation Committee approval. New policy.
12/04/2014 Medical Policy Committee review
12/07/2014 Medical Policy Implementation Committee approval. Policy title and policy statements changed to refer to “hereditary hearing loss” (from “nonsyndromic hearing loss”) to reflect significant overlap between nonsyndromic and syndromic hearing loss.
08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
12/03/2015 Medical Policy Committee review
12/16/2015 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Genetic Testing for Hereditary Hearing Loss

Policy # 00379
Original Effective Date: 12/18/2013
Current Effective Date: 08/09/2021

12/01/2016 Medical Policy Committee review
12/21/2016 Medical Policy Implementation Committee approval. Coverage eligibility unchanged. Policy guidelines section added
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
12/07/2017 Medical Policy Committee review
12/20/2017 Medical Policy Implementation Committee approval. The policy is revised with updated genetics nomenclature. “Mutations” changed to “genes” in policy statements; statements otherwise unchanged. Coverage eligibility unchanged.
12/06/2018 Medical Policy Committee review
12/19/2018 Medical Policy Implementation Committee approval. “Suspected hereditary” added to the first policy statement with coverage eligibility unchanged.
12/05/2019 Medical Policy Committee review
07/02/2020 Medical Policy Committee review
07/08/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
07/01/2021 Medical Policy Committee review
07/14/2021 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 07/2022

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2020 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross
Genetic Testing for Hereditary Hearing Loss

Policy # 00379
Original Effective Date: 12/18/2013
Current Effective Date: 08/09/2021

Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>81252, 81253, 81254, 81430, 81431</td>
</tr>
<tr>
<td>HCPCS</td>
<td>No codes</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
Genetic Testing for Hereditary Hearing Loss

Policy # 00379
Original Effective Date: 12/18/2013
Current Effective Date: 08/09/2021

2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:
   A. In accordance with nationally accepted standards of medical practice;
   B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
   C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.